KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Nov 20, 2026 >>  ABB India 6915  [ -0.62% ]  ACC 1276.45  [ 0.65% ]  Ambuja Cements 399.3  [ 0.58% ]  Asian Paints 2603.35  [ 0.37% ]  Axis Bank 1447  [ 2.05% ]  Bajaj Auto 10778  [ -0.34% ]  Bank of Baroda 286.6  [ 0.39% ]  Bharti Airtel 2155.5  [ 0.39% ]  Bharat Heavy 433  [ -0.23% ]  Bharat Petroleum 312  [ 1.46% ]  Britannia Industries 4890  [ 0.42% ]  Cipla 1414.95  [ -0.07% ]  Coal India 390  [ -0.51% ]  Colgate Palm 1760.6  [ -0.81% ]  Dabur India 394  [ 0.77% ]  DLF 783.5  [ 2.14% ]  Dr. Reddy's Lab. 1390.5  [ -0.54% ]  GAIL (India) 191.45  [ -0.21% ]  Grasim Industries 3102.4  [ -0.07% ]  HCL Technologies 1337  [ 0.41% ]  HDFC Bank 845.25  [ 3.02% ]  Hero MotoCorp 5523  [ -0.59% ]  Hindustan Unilever 2054  [ -0.96% ]  Hindalco Industries 930.3  [ 2.34% ]  ICICI Bank 1641  [ 2.22% ]  Indian Hotels Co. 911.55  [ 2.22% ]  IndusInd Bank 1005  [ 8.88% ]  Infosys 1096.4  [ 0.54% ]  ITC 298.8  [ -0.73% ]  Jindal Steel 1125.35  [ 4.31% ]  Kotak Mahindra Bank 516  [ 3.08% ]  L&T 4201  [ -0.10% ]  Lupin 2010  [ 0.55% ]  Mahi. & Mahi 3541.5  [ 0.89% ]  Maruti Suzuki India 13990.3  [ 2.88% ]  MTNL 24.28  [ -2.18% ]  Nestle India 1326  [ 1.58% ]  NIIT 69.47  [ -0.97% ]  NMDC 69  [ 1.16% ]  NTPC 320.8  [ -1.29% ]  ONGC 223.5  [ -0.45% ]  Punj. NationlBak 155.2  [ -0.13% ]  Power Grid Corpn. 268.5  [ 1.70% ]  Reliance Industries 1375.1  [ 0.37% ]  SBI 1164.95  [ 0.60% ]  Vedanta 237.6  [ -2.38% ]  Shipping Corpn. 256.7  [ 2.87% ]  Sun Pharmaceutical 1885.1  [ -0.94% ]  Tata Chemicals 639.15  [ -1.64% ]  Tata Consumer 1155  [ 1.18% ]  Tata Motors Passenge 266.05  [ 1.04% ]  Tata Steel 177.75  [ -1.69% ]  Tata Power Co. 340  [ 0.00% ]  Tata Consult. Serv. 2375  [ 1.21% ]  Tech Mahindra 1742  [ 1.10% ]  UltraTech Cement 12926.4  [ 2.75% ]  United Spirits 1461  [ -0.27% ]  Wipro 185.5  [ 0.60% ]  Zee Entertainment 71.4  [ -0.07% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

PANACEA BIOTEC LTD.

20 November 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE922B01023 BSE Code / NSE Code 531349 / PANACEABIO Book Value (Rs.) 136.66 Face Value 1.00
Bookclosure 27/09/2024 52Week High 647 EPS 0.00 P/E 0.00
Market Cap. 2057.72 Cr. 52Week Low 292 P/BV / Div Yield (%) 2.46 / 0.00 Market Lot 1.00
Security Type Other

DIRECTOR'S REPORT

You can view full text of the latest Director's Report for the company.
Year End :2026-03 

Your Directors take pleasure in presenting the 42nd Annual Report on the business and operations of the Company together with the
Audited Standalone and Consolidated Financial Statements and the Auditor's Reports thereon for the financial year ended March 31,
2026.

Financial Results

The highlights of standalone and consolidated Financial Results of the Company are summarized below:

Particulars

Standalone

Consolidated

For the year ended

For the year ended

March 31,2026 March 31, 2025

March 31,2026 March 31,2025

Revenue from operations

4,134.92

3,098.55

6,397.74

5,590.94

Other Income

180.03

166.18

169.00

206.60

Total Income

4,314.95

3,264.73

6,566.74

5,797.54

Profit / (Loss) before Interest, Tax, Depreciation & Amortization (EBITDA)

(178.32)

(69.31)

(46.60)

(259.12)

Profit / (Loss) before exceptional items and tax

(438.79)

(260.57)

(268.65)

(439.42)

Exceptional items

-

-

194.96

359.94

Profit / (Loss) before Tax (PBT)

(438.79)

(260.57)

(73.69)

(79.48)

Profit / (Loss) after Tax (PAT)

(299.08)

(152.27)

(71.63)

(87.19)

Total Comprehensive Income / (loss) for the year

(287.60)

(151.74)

(17.37)

(76.09)

Performance Highlights

During the financial year ended March 31,2026, your Company
earned revenues from operations of ?4,134.92 million as
against ?3,098.55 million during the previous financial year. The
increase is mainly on account of higher sales of bOPV vaccine to
UN agencies and Government of India.

The Company's consolidated revenues from operations have
increased to ?6,397.74 million during the financial year under
review as against ?5,590.94 million during the previous
financial year.

On a standalone basis, the Company has registered negative
EBITDA of ?178.32 million during the financial year under review
as against negative EBITDA of ?69.31 million during previous
financial year. The Company has incurred losses before tax of
?438.79 million as against losses before tax of ?260.57 million
during previous financial year.

The Company has incurred consolidated EBITDA loss of ?46.60
million as against loss of ?259.12 million during previous
financial year. The decrease in EBITDA loss is mainly on account
of higher vaccine sales. The consolidated loss before exceptional
items and tax was ?268.65 million during the financial year
under review as compared to loss of ?439.42 million during
previous financial year, mainly due to the reasons as stated
above. The consolidated loss before tax was ?73.69 million
during the year under review as against loss before tax of ?79.48
million during the previous financial year, after considering
exceptional income of ?194.96 million from recognition of
deferred revenue from the sale of pharmaceutical formulation
brands in 2022.

The Company's consolidated loss after tax and exceptional
items for financial year under review has decreased to ?71.63
million as against ?87.19 million during previous financial year

A detailed discussion on the industry overview, external
environment & economic outlook and the Company's
operations for the financial year ended March 31, 2026, is given
in the Management Discussion and Analysis Report forming
part of the Annual Report.

Credit Rating

During the year under review, the Company has neither issued
any debt instruments nor availed any bank facility and has
consequently not carried out any credit rating.

Dividend

In view of the losses during the financial year under review, the
Board of Directors has recommended passing over of dividend
on the Equity as well as Preference Shares of the Company.

In compliance with Regulation 43A of the Securities and
Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 ("SEBI LODR Regulations"),
the Company has in place a Dividend Distribution Policy which
endeavours for fairness, consistency and sustainability while
distributing profits to the shareholders. The same may be
accessed on the Company's website at the link: https://www.
panaceabiotec.com/en/section/information-repository/policy.
Further, there has been no change to any parameters in this
policy during the year.

Transfer to Reserves

Owing to losses, the Board of Directors has not proposed any
transfer of amount to reserves during the financial year under
review.

Share Capital

There has been no change in the capital structure of the
Company during the financial year under review. The issued,
subscribed and paid-up share capital of the Company as

on March 31, 2026, remains unchanged at ?222.62 million
(comprising of ?61.25 million equity share capital divided
into 61,250,746 Equity Shares of ?1 each and ?161.37 million
preference share capital divided into 16,137,000, 0.5% Non¬
Convertible Cumulative Non-Participating Redeemable
Preference Shares of ?10 each). Similarly, the authorised share
capital of the Company also remains unchanged at ?1,223.37
million (comprising of 125,000,000 Equity Shares of ?1 each
and 109,837,000 Preference Shares of ?10 each).

The Company has neither issued any shares or other
convertible securities, nor any equity share with differential
rights / sweat equity shares under Rule 4 & Rule 8 of the
Companies (Share Capital and Debentures) Rules, 2014. The
Company has also neither issued any debentures, bonds, non¬
convertible securities / warrants nor redeemed any debentures
or preference shares, during the year under review.

Significant Events of the Company and its material
subsidiary during the year under review / current year

The Company has, from time to time during the year under
review and thereafter, informed its stakeholders about the
key developments of the Company and its material subsidiary
that took place, by disseminating necessary information to
the stock exchanges and through various other means of
communication.

Some of the key events held during the year under review and
thereafter are mentioned below:

i. Development of Novel Tetravalent Dengue Vaccine
"DengiAll9"
: The Company had collaborated with Indian
Council of Medical Research ("ICMR") in year 2022 for
undertaking Phase III clinical trial for DengiAll®, a single dose
live-attenuated tetravalent vaccine against dengue fever
in adults. The Company had successfully manufactured
3 exhibit batches of drug substances & drug product and
the same was released by Central Drug Laboratory (CDL),
Kasauli following which the Drug Controller General of
India (DCGI) gave necessary permission to undertake the
Phase III clinical trial in India. The Phase III clinical trial
for DengiAll® in adults, was initiated in August 2024. The
clinical trial was successfully conducted at 20 sites with
~10,335 study participants across India. The Company shall
continue to monitor each participant, post administration
of the Investigational Medicinal Product (i.e., vaccine
or Placebo), for a period of two years to examine the
efficacy and immunogenicity of the vaccine. The vaccine is
expected to be launched by 2027-28 post completion of the
clinical trial and subject to receipt of necessary regulatory
approvals.

ii. Receipt of Letter of Award from UNICEF for supply of
bivalent oral polio vaccine (bOPV)
: During the year under
review, the Company has received an additional award
from United Nations Inernational Children's Emergency
Fund (UNICEF) for supply of bOPV worth ~?440 million
in Q3 calendar year (CY) 2025. This additional award is in
continuation to the existing Letter of Award received from
UNICEF last year for supply of bOPV worth ~?1,270 million
in CY2025.

The Company has also received 2 letter of awards from
UNICEF for a long-term agreement starting from April 01,
2026, to March 31,2030, for supply of:

• bOPV worth ~?3,150 million for period of Q2 CY2026
and CY2027; and

• bOPV worth ?780 million in CY2028.

iii. Receipt of Letter of Award from UNICEF for supply of
Pentavalent vaccine, Easyfive-TT®
: During the year under
review, the Company has received an amended Award
from UNICEF for supply of WHO pre-qualified fully liquid
Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib) with
an increased value of ~?470 million during CYs 2026 and
2027. The Company has also received an additional award
for supply of Easyfive-TT® worth ~?330 million in the CY
2027.

This Letter of Award is in continuation to the existing long¬
term supply award received from UNICEF earlier for supply
of Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib)
worth ~?8,130 million to UNICEF during CYs 2023-2027.

iv. Receipt of award from PAHO for supply of Easyfive-TT:
During the year under review, the Company has received
an award from Pan American Health Organization ("PAHO")
for supply of Diphtheria-Tetanus-Pertussis-Hepatitis
B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine
(Pentavalent) - Liquid (single dose) ("Easyfive-TT") worth
~?410 million during CYs 2026 and 2027.

v. Receipt of Letter of Acceptance from CMSS for supply of
bOPV
: During the year under review, the Central Medical
Services Society, Ministry of Health and Family Welfare,
Government of India ("CMSS") has accepted the Company's
offer for supply of bOPV worth ~?1,272 million in several
tranches over a period of 90 - 480 days, against the tender
issued by it in this regard.

vi. Receipt of Letter of Award from CMSS for supply of
Diphtheria and Tetanus Vaccine (Absorbed) for Adults
and Adolescents IP
: During the current year, the Company
has received a letter of award from CMSS for supply of
Diphtheria and Tetanus Vaccine (Absorbed) for Adults and
Adolescents IP ("Td Vaccine") worth ~?208 million from
September / October 2026 till November / December 2028.

vii. Inclusion of EmulsiPan adjuvant in the CEPI Adjuvant
Library
: The Company got listed one of its adjuvant
products, EmulsiPan in the Coalition for Epidemic
Preparedness Innovations (CEPI) Library of adjuvants to
support the scientific community in advancing vaccine
and biotherapeutic development. EmulsiPan is an oil-
in-water emulsion adjuvant and is produced by nano¬
emulsification of squalene along with surfactants and
buffers. It is a ready-to-use sterile emulsion, supplied in
a 10 ml. USP Type I glass vial for research purposes. It is
designed for storage at 2-8°C and maintains stability for
over 2 years under recommended conditions. EmulsiPan
does not require any licensing fees - ensuring affordability
and providing open access for vaccine developers.
Research institutes and companies that are looking for
adjuvants can now contact the Company for commercial
or research programs.

viii. Launch of DENSTAR Project: On June 01, 2026, a
collaborative research project, namely DENSTAR, which
will work to advance the licensure of the dengue vaccine
DengiAll® in sub-Saharan Africa (sSA) and to facilitate
its broader global use has been launched. The DENSTAR
project is coordinated by the "Sclavo Vaccines Association",
a non-profit organization based in Siena (Italy) devoted to
support vaccine research and development in developing
countries. The DENSTAR consortium unites 10 Partners
from 9 countries across Europe, Africa, the United States,
India and South Korea which comprises of universities,
research organizations, a biotech company and a non¬
profit organization, bringing together experts, researchers,
regulators, healthcare practitioners. The Company being
the developer of DengiAll®, a tetravalent dengue vaccine
targeting all four virus serotypes and currently in late-stage
development in India, is a key partner of the DENSTAR
consortium. This diverse and complementary consortium
embodies a great public-private partnership, fully aligned
with the DENSTAR project's goal to promote broader
use of DengiAll® in Africa and globally, contributing to
equitable access to safe and effective dengue prevention
tools.

ix. Strategic expansion into Baby Care Products: The
Company's wholly owned subsidiary, Panacea Biotec
Pharma Limited ("PBPL") has launched India's first 100%
toxin-free and safe Baby Skin Care products (Baby Massage
Oil, Baby Head to Toe Wash, Baby Daily Lotion and Diaper
Rash Cream) under the existing brand name "NikoMom®"
and Infant Milk Substitute (IMS) product under the brand
name "Staart® Prime" with Stages 1 and Stages 2-3-4. These
new products range falls under the Baby skin care and
infant milk substitute category and is aimed currently at
serving the domestic market. With a strong foundation in
science and research, PBPL aims to offer well-researched,
high-quality products that support infant health beyond
vaccination.

Also, PBPL's scientifically formulated oral nutritional
supplement - ChilRun full® has demonstrated considerable
success in enhancing childhood growth, especially among
ones at risk of malnutrition, according to the results of
a comprehensive 90-day nationwide post-marketing
observational study, conducted by PBPL.

x. Settlement of Dispute with Apotex: The Parties have
executed a Settlement Agreement on July 09, 2025, recording
full and final settlement of the disputes forming part of
the arbitration among Apotex Inc., the Company and its
wholly-owned subsidiary, Panacea Biotec Pharma Limited.

Pursuant to the settlement, it has, inter-alia, been agreed
among the Parties that:

• Apotex will pay US$ 2.5 million within 30 days from the
date of Settlement Agreement. This amount had already
been received by PBPL as per the agreed terms;

• Apotex will also pay US$ 2.5 million upon receipt of final
USFDA approval of the ANDA that is the subject of the
Collaboration Agreement for Paclitaxel Protein-Bound
Particles for Injectable Suspension (Albumin-Bound)
("Paclitaxel");

• the profit share for the supply by PBPL of Paclitaxel
for Canada will be modified in a way that Apotex shall
receive 65% of the Net Profits and PBPL shall receive
balance 35% until such time that Apotex earns profit of
US$ 1.5 million from that supply, after which the profit
share shall revert to 50:50;

• the profit share for the supply by PBPL of Paclitaxel for
USA will be modified in a way that Apotex shall receive
60% of the Net Profits and PBPL shall receive balance
40% until such time that Apotex earns profit of US$ 0.5
million from that supply, after which the profit share
shall revert to 50:50.

The Tribunal has issued the consent award on September
12, 2025, recording the settlement terms and termination
of the arbitrations pursuant to the aforesaid Settlement
Agreement.

xi. Site Inspection by National Centre for Public Health and
Pharmacy, Hungary ("NCPHP")
: NCPHP has conducted an
inspection of the manufacturing facility of PBPL at Baddi,
Himachal Pradesh, India in January 2026. Following the
inspection, NCPHP issued a "Statement of non-compliance
with Good Manufacturing Practice", wherein NCPHP has
considered that the Facility does not comply with the
GMP requirements, resulting in revocation of all valid GMP
certificates issued by NCPHP. NCPHP has proposed halting
supplies of non-vital products, except those supplying
patients being on treatment with oncology products.

However, officials of NCPHP did not observe any behaviour
or manufacturing process that would pose risk to the
quality of products already released. Further, PBPL is not
supplying any oncology related products in European
Union markets. PBPL has implemented comprehensive
corrective and preventive actions (CAPA) and has requested
for re-inspection at the earliest possible opportunity to
restore the GMP Certificates.

Apart from the updates mentioned above and disclosed
elsewhere in the Annual Report, there were no significant
events during and after the end of the financial year ended
March 31,2026.

Employee Stock Options

The Company has an approved Employee Stock Option Plan
2020 ("ESOP 2020") for the employees of the Company and its
subsidiaries. However, no options have been granted under
ESOP 2020 till date.

Significant and material orders impacting the going
concern status and Company's operations in future

During the year under review, no significant and material
order was passed by any regulator or court or tribunal which
may impact the going concern status and your Company's
operations in future.

However, during the financial year 2011-12, a search
operation was conducted by the Income Tax Department at
the Company's premises and hence, the Company re-filed its
income tax returns for the Assessment Years ("AY") 2006-07
to 2012-13. During the financial year 2014-15, the Income Tax
Department completed the assessments for the said years,
disallowed certain expenses, and raised a demand of ?3,294.90
million (including interest) on various grounds.

The Company preferred appeals before the CIT (Appeals)
against these assessment orders. Following several hearings,
the CIT (Appeals) ruled in favour of the Company and deleted
the entire demand of ?3,294.90 million. However, the CIT
(Appeals) sustained certain disallowances amounting to
?60.20 million for AY 2010-11 and AY 2011-12, against which

the Company filed appeals before the Hon'ble Income Tax
Appellate Tribunal ("ITAT"). The Income Tax Department also
cross-appealed before ITAT against the orders of the CIT
(Appeals).

During the financial year 2025-26, the Hon'ble ITAT, vide its
consolidated Order dated February 27, 2026, passed the
following rulings:

• Dismissed all seven appeals filed by the Income Tax
Department against the orders of the CIT (Appeals) for AY
2006-07 to AY 2012-13.

• Allowed both appeals filed by the Company against the CIT
(Appeals) orders dated July 27, 2015, for AY 2010-11 and AY
2011-12.

• Quashed the underlying assessment orders passed by
the Assessing Officer / DCIT for AY 2006-07 to AY 2012-13,
thereby providing complete relief to the Company.

Consequently, there are no subsisting tax demands or adverse
orders from this matter that impact the Company's operations
or going concern status.

Report on Corporate Governance

Your Company has always placed thrust on managing its affairs
with diligence, transparency, responsibility and accountability.
The Board supports the broad principles of Corporate
Governance and lays emphasis on its role in aligning and direct
the actions of the Company in achieving its objectives. Your
directors reaffirm their commitment to adhere to the highest
corporate governance and ethical practices. The Company
has complied with the requirements of the SEBI LODR
Regulations regarding corporate governance. In compliance
with Regulation 34(3) of the SEBI LODR Regulations, a report
on corporate governance for the financial year under review
is presented in a separate section titled "Report on Corporate
Governance" and forms an integral part of the Annual Report.
The requisite certificate from M/s R&D Company Secretaries,
Secretarial Auditors, confirming compliance with the conditions
of Corporate Governance is annexed thereto and forms part of
the Annual Report.

Management Discussion and Analysis Report

Pursuant to Regulation 34(3) of the SEBI LODR Regulations,
Management Discussion and Analysis Report for the year
under review, is presented in a separate section and forms an
integral part of the Annual Report.

Business Responsibility and Sustainability Report

Under SEBI LODR Regulations and relevant circulars (dated May
10, 2021, and January 30, 2026), the top 1,000 listed companies
by market capitalization are mandated to file a Business
Responsibility and Sustainability Report ("BRSR") with effect
from 2023.

Although the Company did not rank among the top 1,000
listed entities by market capitalization as on December 31,
2025, it continues to comply with the relevant BRSR provisions
under Regulation 3(2) of the SEBI LODR Regulations, based on
its previous market capitalization.

Accordingly, as required under Regulation 34(2)(f) of the SEBI
LODR Regulations, BRSR forms an integral part of this Annual
Report and is presented in a separate section. It highlights the
Company's key initiatives across Environmental, Social, and
Governance (ESG) domains.

Subsidiaries, Associates and Joint Ventures

A. Subsidiaries

As on March 31, 2026, your Company had 3 Wholly-owned
Subsidiary ("WOS") companies, viz. Panacea Biotec Pharma
Limited ("PBPL"), Meyten Realtech Private Limited ("Meyten")
and Panacea Biotec (International) S.A. ("PBS"), Switzerland and
2 indirect WOS companies, viz. Panacea Biotec Germany GmbH
("PBGG"), the WOS of PBS & Panacea Biotec Inc. ("PB Inc."), USA,
the WOS of PBPL.

PBPL is engaged in the research, development, manufacturing
and marketing of pharmaceutical formulations, nutrition, infant
milk substitutes & baby care products in India and international
markets. As on March 31, 2026, the Company holds 1,000,000
equity shares of ?1 each in PBPL.

Meyten owns an immovable property at New Delhi which is
leased out to the Company. As on March 31,2026, the Company
holds 48,76,319 equity shares of ?1 each in Meyten.

PBS was earlier engaged in the business of trading
pharmaceutical products and is currently not pursuing any
business. The Company holds 6,000 equity shares of CHF 100
each with an investment of ?34.36 million in PBS as on March
31, 2026.

PBGG is engaged in marketing of pharmaceutical products
including the Company's products in Germany. PBGG is
proposed to be converted into direct WOS of the Company by
way of acquisition of 100% shares of PBGG by PBL from PBS.
PBS has an investment of €0.25 million in PBGG.

PB Inc. was set up to carry on the business of buying, selling,
marketing, importing, exporting, distributing, and dealing in
services and products related to health and wellness, such as
nutrition, dietary supplements, OTC drugs, medical devices,
prescription drugs, and vaccines. It is a wholly owned subsidiary
of PBPL. However, since no activity is undertaken by PB Inc. due
to regulatory challenges, it has been decided to close PB Inc.
PBPL holds 100 million common stock of US$ 0.01 each in PB
Inc. with an investment of US$ 1.00 million as on March 31,
2026.

B. Joint Ventures and Associates

As on March 31, 2026, your Company has 1 joint venture
company, viz. Adveta Power Private Limited ("Adveta") and
1 associate company, viz. PanEra Biotec Private Limited
("PanEra"). Adveta and PanEra have been accounted for in the
consolidation of financial statements pursuant to the provisions
of Indian Accounting Standards ("Ind AS").

Adveta: The Company's 50:50 joint venture with PanEra,
was earlier granted in-principle approval by the Government
of Arunachal Pradesh for allotment of two Power Projects
of 80 MW and 75 MW in financial year 2012-13 which were
subsequently cancelled. As part of business restructuring,
restructuring proposals are under consideration to integrate
Adveta into the other group entity.

PanEra: PanEra was granted in-principle approval by the
Government of Himachal Pradesh for allotment of a hydropower
project of 4 MW, in earlier years. However, no major investment
has been made in this regard. As part of business restructuring,
restructuring proposals are under consideration to integrate
PanEra into the other group entity so that the same can move
towards net zero carbon emission and use energies which are

sustainable and good for the environment and at the same
time economical to the respective entity.

Pursuant to Regulation 46(2)(h) of the SEBI LODR Regulations,
the Company has formulated a Policy for determining material
subsidiaries which may be accessed on the Company's website
at the link: https://www.panaceabiotec.com/en/section/
information-repository/policy.

As on March 31,2026, as well as on the date of this Report, PBPL
is the only material subsidiary of the Company pursuant to the
SEBI LODR Regulations.

Financial Details of Subsidiaries, Associates and Joint
Ventures

Pursuant to the provisions of Section 129(3) of the Companies
Act, 2013 ("the Act"), a separate statement containing the
salient features of financial statements, performance and
financial position of each of the Company's Subsidiaries,
Associates and Joint Venture, in the prescribed Form AOC-1,
forms part of the financial statements and hence not repeated
here for the sake of brevity. The contribution of the Subsidiaries,
Joint Venture and Associate and to the overall performance of
your Company is outlined in Note No. 48 of the Consolidated
Financial Statements for the financial year ended March 31,
2026.

In accordance with the provisions of Section 136 of the Act read
with SEBI LODR Regulations, the standalone and consolidated
financial statements of the Company and all other documents
required to be attached thereto are available on the website of
the Company and can be accessed at https://www.panaceabiotec.
com/en/section/information-repository/annual-report

The financial statements of the subsidiaries are available on
the website of the Company at https://www.panaceabiotec.
com/en/section/information-repository/subsidiaries-financial-
information. The financial statements of the subsidiaries will also
be made available upon request of any Member of the Company
who is interested in obtaining the same.

Consolidated Financial Statements

The Consolidated Financial Statements of the Company and
its Subsidiaries, Associate and Joint Venture, prepared in terms
of Section 129 of the Act, Regulation 33 of the SEBI LODR
Regulations and in accordance with Ind AS 110 read with Ind
AS 28 and 31 as specified in the Companies (Indian Accounting
Standards) Rules, 2015 ("Ind AS Rules") and provisions of
Schedule III to the Act, together with Auditor's Report thereon,
forms part of the Annual Report.

Indian Accounting Standards, 2015

The annexed financial statements comply in all material aspects
with Indian Accounting Standards notified under Section 133 of
the Act, the Ind AS Rules and other relevant provisions of the Act.

Listing of Equity Shares

The Equity Shares of the Company continue to be listed on
National Stock Exchange of India Limited ("NSE") and BSE
Limited ("BSE"). The requisite annual listing fees for the financial
year 2026-27 have been paid to these Exchanges well within
the due dates.

Public Deposits

During the year under review, your Company has neither

invited nor accepted any deposits from the public / members
pursuant to the provisions of Sections 73 and 76 of the Act read
with the Companies (Acceptance of Deposits) Rules, 2014 and
therefore, no amount of principal or interest was outstanding
in respect of deposits from the Public as on the date of the
balance sheet.

During the year under review, the Company has also not availed
any loan from any of its directors. The details of outstanding
loans received from the director of the Company have been
disclosed in Note No. 41 to the Standalone Financial Statements
forming part of the Annual Report.

Directors and Key Managerial Personnel

During the financial year under review and thereafter, the
following changes were held in the composition of the Board
of Directors and Key Managerial Personnel ("KMP") of the
Company:

i. Cessation / Completion of tenure of non-executive
independent director: Mr. Mukul Gupta (DIN: 00254597),
independent director, has ceased to be director of the
Company upon completion of his second and final term on
March 31, 2026.

CA Rajesh Jain (DIN: 10619014), independent director has
ceased to be director of the Company on account of his
resignation from directorship w.e.f. close of business hours
on June 30, 2026.

Your directors express their deep appreciation and
gratitude to the aforesaid directors for their extensive
contribution and guidance received towards the business
growth of the Company.

ii. Appointment of non-executive independent director:
Based on the recommendation of the Nomination and
Remuneration Committee ("NRC") of the Board, the Board
has appointed Mr. Rajinder Singh Manku (DIN: 09706881)
as an additional director in the capacity of non-executive
independent director of the Company for a period of 5 years
w.e.f. July 01,2026, subject to approval of shareholders. The
terms and conditions for his appointment are contained in
the Explanatory Statement forming part of the Notice of the
ensuing Annual General Meeting ("AGM") of the Company.

In the opinion of the Board, he is a person of integrity and
possess requisite expertise and experience for appointment
as independent director of the Company.

iii. Change in Chief Financial Officer ("CFO"): Mr. Devender
Gupta, Chief Financial Officer and Head Information
Technology designated as KMP has ceased to be CFO of the
Company on account of his resignation from the services of
the Company w.e.f. December 15, 2025.

Mr. Vinod Goel who was earlier acting as Group CFO and
Head Legal & Company Secretary as well as Compliance
Officer of the Company has been appointed as Chief
Financial Officer designated as Group Chief Financial
Officer and Head Legal & Corporate Governance under the
category of KMP of the Company w.e.f. December 16, 2025.

iv. Change in Company Secretary: Mr. Vinod Goel who was
acting as Group Chief Financial Officer and Head Legal &
Company Secretary under the category of KMP has ceased
to be Company Secretary of the Company on account of
change in his role w.e.f. December 16, 2025.

Mr. Ankit Jain (Membership No. : A29499) has been
appointed as Company Secretary and Compliance Officer
designated as General Manager - Legal & Company
Secretary of the Company under the category of KMP w.e.f.
December 16, 2025.

v. Directors Retiring by Rotation: In accordance with the
provisions of Section 152 of the Act and Article 119 of the
Articles of Association of the Company, Mr. Ankesh Jain
(DIN: 03556647) and Mr. Harshet Jain (DIN: 08732974),
Whole-time Directors of the Company are liable to retire
by rotation. Being eligible they have offered themselves
for re-appointment as directors at the ensuing AGM of the
Company.

vi. Profile of Directors seeking appointment / re-appointment:
The brief resume of the Directors seeking appointment /
re-appointment along with other details as stipulated
under Regulation 36(3) of the SEBI LODR Regulations and
Secretarial Standards issued by The Institute of Company
Secretaries of India, are provided in the Notice convening
the ensuing AGM of the Company and the Corporate
Governance Report forming part of the Annual Report.

vii. Declaration of independence / compliance with Code
of Conduct: In terms of Section 149 of the Act and the
SEBI LODR Regulations, Mrs. Ambika Sharma, Mr. Krishan
Kumar Jalan, Dr. Rajender Pal Singh, Mr. Rajinder Singh
Manku and Dr. Venkatesh Sarvasiddhi are the independent
directors of the Company as on the date of this Report.

All the independent directors of the Company have
given declarations under Section 149(7) of the Act, that
they continue to meet the criteria of independence
as laid down under Section 149(6) of the Act and
Regulation 16(1 )(b) of the SEBI LODR Regulations. In
terms of Regulation 25(8) of the SEBI LODR Regulations,
the independent directors have confirmed that they are
not aware of any circumstance or situation, which exists
or may be reasonably anticipated, that could impair or
impact their ability to discharge their duties with an
objective independent judgement and without any
external influence. The independent directors have also
affirmed compliance with the Code of Conduct laid down
by the Board of Directors for all the Board Members,
Senior Management Personnel and other employees of
the Company, during the year under review.

viii. Registration in Independent Directors' Data Bank:
The Company has received confirmation from all its
independent directors that they are registered in the
Independent Directors' Data Bank of the Indian Institute of
Corporate Affairs at Manesar in terms of Section 150 of the
Act read with Rule 6 of the Companies (Appointment and
Qualification of Directors) Rules, 2014.

All the above appointments / re-appointments by the Board
of Directors are based on the performance evaluation and
recommendation of the Nomination and Remuneration
Committee of the Board of Directors. Your directors recommend
appointment / re-appointment of directors as stated above, in
the ensuing AGM.

Apart from the above, there is no other change in the Directors
and Key Managerial Personnel during the year under review
and thereafter.

Board Evaluation

The Board has, in consultation with its NRC, formulated a
framework containing, inter-alia, the criteria for performance
evaluation of the entire Board of the Company, its Committees
and individual Directors, including independent directors.

A structured questionnaire covering the performance of the
Board as a whole, Board Committees and individual directors
were circulated to all the Board members. The questionnaire
sought inputs on various aspects of governance, strategy,
oversight, Board dynamics, and individual contribution. The
above criteria are broadly based on the Guidance Note on
Board Evaluation issued by the SEBI and ICSI.

In accordance with the said framework, an annual performance
evaluation of the Board of Directors, its Committees and
individual directors was carried out by the Board in terms
of the provisions of Section 134(3)(p) of the Act read with
Rule 8(4) of the Companies (Accounts) Rules, 2014 ("Account
Rules"). In compliance with Regulation 17(10) of the SEBI LODR
Regulations, the Board carried out performance evaluation of
independent directors without the participation of director
being evaluated.

The Board evaluated its performance after seeking inputs
from all the Directors on the basis of criteria such as the
Board composition and structure, effectiveness of Board
processes, information and functioning, etc. The performance
of the Committees was evaluated by the Board after seeking
inputs from all the directors on the basis of criteria such as
the composition of Committees, effectiveness of Committee
meetings, etc.

The Board and the NRC reviewed the performance of individual
Directors on the basis of criteria such as the contribution of the
individual Director to the Board and Committee Meetings like
preparedness on the issues to be discussed, meaningful and
constructive contribution and inputs in meetings, etc.

In a separate meeting of independent directors, performance
of non-independent directors, the Board as a whole and
the Chairman was evaluated, taking into account the views
of Executive and non-executive directors. The exercise was
carried out through a structured evaluation process covering
various aspects such as Board composition & quality, strategic
& risk management, board functioning, etc. which are briefly
stated in the Corporate Governance Report, forming part of the
Annual Report. The independent directors also assessed the
quality, quantity and timeliness of flow of information between
the Company Management and the Board that is necessary for
the Board to effectively and reasonably perform their duties.
The views and suggestions expressed at the said meeting were
noted.

The above evaluations were then discussed in the Board
Meeting and performance evaluation of independent directors
was done by the entire Board, excluding the independent
director being evaluated. Performance evaluation of
independent directors was conducted based on criteria such
as ethics and values, knowledge and proficiency, behavioural
traits, etc. The Board of Directors has expressed its satisfaction
with the evaluation process.

Board Meetings

Pursuant to the provisions of Section 173(1) of the Act and
Regulation 17(2) of the SEBI LODR Regulations, during the

year under review, 5 (five) Board Meetings were held on May
30, 2025, August 14, 2025, November 14, 2025, December 15,
2025, and February 11,2026. The intervening gap between two
Board Meetings was within the maximum period prescribed
under the Act. The detailed information including attendance
thereat is furnished in the Report on Corporate Governance,
forming part of the Annual Report.

Board Committees and number of meetings of the Board
Committees

In compliance with the requirements of the Act and SEBI
LODR Regulations, your Board had constituted various Board
Committees inter-alia including Audit Committee, Nomination
and Remuneration Committee, Stakeholders' Relationship
Committee and Risk Management Committee. The details
of the composition and number of meetings of the Board
Committees held during the financial year under review
including attendance thereat, are furnished in the Report on
Corporate Governance, forming part of the Annual Report.
During the year under review, all the recommendations made
by these Committees were accepted by the Board.

Policy on Directors' appointment & remuneration

The management of the Company is immensely benefitted from
the guidance, support and matured advice from the members
of the Board who are also members of various committees. The
Board consists of directors possessing diverse skills and rich
experience to enhance the quality of its performance. Pursuant
to the provisions of Section 178(3) of the Act, Regulation 19(4) of
the SEBI LODR Regulations and based on the recommendations
of the NRC of the Board, the Board has adopted a policy for
selecting, appointment and remuneration of the Directors,
Key Managerial Personnel, Senior Management Personnel
and other employees of the Company. This policy may be
accessed on the Company's website at the link: https:// www.
panaceabiotec.com/en/section/information-repository/policy.

The policy includes criteria for determining qualifications,
positive attributes and independence of directors. It also,
inter-alia, covers guiding principles and components such
as fixed or variable remuneration, retirement benefits, and
commissions. In terms of the policy, the NRC evaluates
balance of skills, knowledge and experience of Directors, Key
Managerial Personnel or Senior Management Personnel whom
it recommends to the Board for appointment. The components
of remuneration policy are briefly stated in the Report on
Corporate Governance, forming part of the Annual Report.

Selection and procedure for nomination and appointment
of Directors

The NRC is responsible for developing competency
requirements for the Board based on the industry and strategy
of the Company. The Board composition analysis reflects in¬
depth understanding of the Company, including its strategies,
environment, operations, financial condition and compliance
requirements.

The NRC conducts a gap analysis to refresh the Board on a
periodic basis, including each time a director's appointment
or re-appointment is required. The NRC reviews and vets
the profiles of potential candidates vis-a-vis the required
competencies, undertakes due diligence and meeting
potential candidates, prior to making recommendations of
their nomination to the Board.

Energy Conservation, Technology Absorption & Foreign
Exchange

Pursuant to Section 134(3)(m) of the Act read with Rule 8
of the Companies (Accounts) Rules, 2014 ("Accounts Rules")
particulars regarding conservation of energy, technology
absorption and foreign exchange earnings & outgo, are given
in
Annexure A hereto and forms part of this Report.

Annual Return

As required pursuant to Section 92(3) and 134(3)(a) of the
Act, the draft Annual Return of the Company as on March
31, 2026, is available on the Company's website at: https://
www.panaceabiotec.com/en/section/information-repository/
annual-return.

Related Party Transactions

During the year under review, all the related party transactions
entered into were on an arm's length basis and predominantly
in the ordinary course of business. As per the latest audited
financial statements, the Company has not entered into any
material related party transactions as referred to in Section
188 of the Act. Accordingly, the disclosure of Related Party
Transactions as required under Section 134(3)(h) of the Act
read with Rule 8(2) of the Accounts Rules in the prescribed
Form AOC- 2 is not applicable. Suitable disclosures as required
under Ind AS 24 have been made in the notes to the Financial
Statements forming part of the Annual Report. Apart from
remuneration / sitting fees and consultancy charges in
professional capacity, there is no pecuniary transaction with
any director, which had potential conflict of interest with the
Company.

All the related party transactions are placed before the Audit
Committee for its review and further recommendation to
the Board for its approval. Wherever applicable, approval is
obtained for related party transactions which are of repetitive
nature and/or entered in the ordinary course of business and
are at arm's length basis.

As per the provisions of the Act and Regulation 46(2)(g) of the
SEBI LODR Regulations, your Company has formulated a policy
on Materiality of related party transactions and dealing with
related party transactions which is available on the Company's
website at the link: https://www.panaceabiotec.com/en/
section/information-repository/policy.

The policy intends to ensure that proper reporting, approval
and disclosure processes are in place for all transactions
between the Company and the related parties. This policy
specifically deals with the review and approval of material
related party transactions keeping in mind the potential or
actual conflicts of interest that may arise because of entering
into these transactions.

Particulars of employees and related disclosures

Disclosure pertaining to remuneration and other details as
required under Section 197(12) of the Act read with Rule
5(1) of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014 ("Managerial Personnel
Rules") are provided in
Annexure B hereto and the same forms
part of this Report.

In terms of the provisions of Section 197(12) of the Act read
with Rules 5(2) and 5(3) of the Managerial Personnel Rules, a
statement containing particulars of top 10 employees and the

employees drawing remuneration in excess of the limits set out

in the said Rules, are provided in Annexure C hereto and the

same forms part of this Report.

Auditors and Audit Reports

i) Statutory Auditors and Audit Report: Pursuant to the
provisions of Section 139 of the Act read with rules framed
thereunder, M/s Suresh Surana & Associates LLP, Chartered
Accountants (Firm's Regn. No. 121750W/W100010) were
appointed as the Statutory Auditors of the Company
for a term of 5 consecutive years to hold office from the
conclusion of 40th AGM upto the conclusion of 45th AGM of
the Company to be held in the year 2029.

Pursuant to Section 141 of the Act, the Statutory
Auditors have confirmed that they are not disqualified
from continuing as Auditors of the Company and their
appointment meets the eligibility criteria prescribed in
Section 141(3)(g) and 147 of the Act. They also confirmed
that they are independent, maintained an arm's length
relationship with the Company and that no orders or
proceedings were pending against them before the Institute
of Chartered Accountants of India or any competent court /
authority relating to matters of professional conduct.

The Auditor's Report on the standalone as well as
consolidated financial statements for the financial year
ended March 31, 2026, does not contain any qualification,
reservation or adverse remark. The said Reports were issued
by the Statutory Auditors with an unmodified opinion.
However, the Statutory Auditors have, in their report on
standalone financial statements, drawn attention to Note
48 of the standalone financial statements, which states
that the Company has incurred losses (including other
comprehensive income) amounting to ?287.3 million for
the year ended March 31, 2026, and the retained earnings
are negative to the extent of ? 2,178.2 million as on
March 31, 2026. These conditions indicate that a material
uncertainty exists that may cast significant doubt on the
Company's ability to continue as a going concern.

In this regard, as disclosed in note no. 48, the retained
earnings of the Group are positive to the extent of ?7,760.5
million. The surplus funds remaining with the Group out of
the sales of pharmaceutical formulations brands in India
and Nepal in March 2022 have helped in strengthening
the working capital position, setting up new facilities
for enhancement of capacities for manufacturing of
vaccines drug substance, scaling up Group's nutrition and
pharmaceutical formulations business and pursuing other
business opportunities. The Company has already received
higher long-term awards from United Nations Children's
Fund (UNICEF) and Pan American Health Organisation for
supply of pentavalent vaccine and awards from UNICEF
for supply of bivalent oral polio vaccine. Based on these
measures and continuous efforts to improve the business
performance, the management has prepared the financial
statements on going concern basis.

The Key Audit Matters as contained in the Auditor's
Report on the Standalone Financial Statements are also
mentioned as Key Audit Matters in the Auditor's Report on
the Consolidated Financial Statements in a similar manner.

The management response to the observations / comments
/ key audit matters contained in the Auditor's Report and
Annexure thereto has been suitably given in the respective

Notes to the Standalone as well as Consolidated Financial
Statements referred to therein.

The notes to accounts and other observations, if any, in the
Auditor's Reports are self-explanatory and therefore, do not
call for any further comments.

ii) Cost Accounts and Auditors: The Company is required
to maintain cost records as specified by the Central
Government under Section 148(1) of the Act and
accordingly, such accounts and records have been duly
made and maintained by the Company in compliance with
the provisions of the Act.

Pursuant to the provisions of Section 148 of the Act read
with the Companies (Cost Records and Audit) Rules, 2014,
the Board has appointed M/s Jain Sharma & Associates,
Cost Accountants (Firm's Registration Number: 000270) as
the Cost Auditors to conduct the audit of the Company's
Cost Records for the financial year ended March 31,2026,
and their remuneration was ratified by the shareholders in
the 41st AGM of the Company held on September 30, 2025.

The cost audit for the financial year 2025-26 is in progress
and the Cost Auditor's Report will be submitted with the
Central Government within the prescribed time. The Cost
Audit Report for the financial year 2024-25 was filed on
September 10, 2025.

Based on the recommendations of the Audit Committee,
the Board of Directors has in its meeting held on May
30, 2026, re-appointed M/s Jain Sharma & Associates,
Cost Accountants, as Cost Auditors of the Company to
conduct the audit of the Company's Cost Records for
the financial year 2026-27. M/s Jain Sharma & Associates
have confirmed their independence and arm's length
relationship with the Company and that they are free from
the disqualifications specified in Section 139, 141 of the
Act and their appointment meets the eligibility criteria as
prescribed in Section 141(3)(g) and 148 of the Act. They
have also confirmed that no orders or proceedings were
pending against them relating to matters of professional
conduct before the Institute of Cost Accountants of India or
any competent court / authority.

In compliance with Rule 14 of the Companies (Audit
and Auditors) Rules, 2014, an item for ratification of
remuneration of cost auditor for conducting the audit for
the financial year 2026-27 has been included in the Notice
of the ensuing AGM for shareholders' approval.

iii) Secretarial Auditors and Secretarial Audit Report:

Pursuant to the provisions of Section 204 of the Act read with
Rule 9 of the Managerial Personnel Rules and Regulation
24A of the SEBI LODR Regulations, M/s R&D Company
Secretaries, a peer reviewed firm of Practicing Company
Secretaries were appointed as Secretarial Auditors to
conduct the secretarial audit of the Company for a term
of five consecutive years commencing from Financial Year
2025-26 to Financial Year 2029-30 at the 41st AGM held on
September 30, 2025. M/s R&D Company Secretaries have
confirmed that they are not disqualified from continuing as
Secretarial Auditors of the Company. The Secretarial Audit
Report issued by them is annexed as
Annexure D to this
Report.

The Secretarial Audit Report does not contain any
qualification, reservation or adverse remarks. However,

it contains two observations relating to (i) delayed
payment to Micro and Small Enterprises beyond the
period prescribed under Section 15 of the Micro, Small
and Medium Enterprises Development Act, 2006 (MSMED
Act); and (ii) inadvertent delays in filing two routine
statutory e-forms (IEPF-2 and MGT-14) with the Registrar
of Companies (RoC). In this regard, (i) the Company has
made the requisite provision for the interest amount on
such delayed payment to aforesaid vendors in accordance
with Section 16 of the MSMED Act and disclosed such
delays in MSME Form I; and (ii) the delay in filing of
IEPF-2 was on account of continuous technical errors or
login failures on the Ministry of Corporate Affairs (MCA)
V3 portal and delay in filing of MGT-14 was due to an
unintentional clerical error / oversight by the compliance
team. However, the Company has taken corrective action
and subsequently all such pending e-forms have been
filed with additional fees.

In compliance with the requirements of the SEBI LODR
Regulations, the material unlisted subsidiary of the
Company, viz. Panacea Biotec Pharma Limited had also
appointed M/s R&D Company Secretaries, a peer reviewed
firm of Practicing Company Secretaries as Secretarial Auditors
to conduct the secretarial audit for the financial year ended
March 31,2026. The Secretarial Audit Report issued by them
to PBPL is annexed as
Annexure E to this Report.

The said Secretarial Audit Report does not contain any
qualification, reservation or adverse remarks. However, it
contains one observation relating to delayed payment to
Micro and Small Enterprises beyond the period prescribed
under Section 15 of the MSMED Act. PBPL has made the
requisite provision for the interest amount on such delayed
payment to aforesaid vendors in accordance with Section
16 of the MSMED Act and disclosed such delays in MSME
Form I.

In addition to the above and in compliance with Regulation
24A(2) of the SEBI LODR Regulations, Annual Secretarial
Compliance Report issued by M/s R&D Company Secretaries,
Secretarial Auditors, for the financial year ended March 31,
2026, has been submitted with the stock exchanges within
prescribed time.

Material changes and commitments affecting the financial
position

As required under Section 134(3) of the Act, the Board of
Directors inform the Members that during the financial year
under review, there have been no material changes, except as
disclosed elsewhere in the Annual Report:

• in the nature of Company's business;

• in the Company's subsidiaries, associate and joint venture
or in the nature of business carried out by them; and

• in the classes of business in which the Company has an
interest.

Further, except as disclosed elsewhere in the Annual Report,
there have been no material changes and commitments which
could affect the financial position of the Company between the
end of the financial year and the date of this Report.

Compliance with Secretarial Standards

The Company has followed applicable Secretarial Standards i.e.

SS-1 and SS-2, relating to 'Meetings of the Board of Directors'
and 'General Meetings', respectively, issued by the Institute of
Company Secretaries of India.

Transfer to Investor Education and Protection Fund

Pursuant to the provisions of Section 124 of the Act, Investor
Education and Protection Fund Authority (Accounting, Audit,
Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the
relevant circulars and amendments thereto, the amount of
dividend remaining unpaid or unclaimed for a period of 7 years
from the due date is required to be transferred to the Investor
Education and Protection Fund ("IEPF"), constituted by the
Ministry of Corporate Affairs, Government of India. During the
year under review, there was no amount of dividend remaining
unpaid or unclaimed for a period of 7 years from the due date.
Accordingly, no amount was required to be transferred by the
Company to the IEPF.

Pursuant to the provisions of IEPF Rules, all the shares in respect
of which any dividend which has not been paid or claimed for 7
consecutive years is required to be transferred by the Company
to the designated Demat Account of the IEPF Authority ('IEPF
Account') within a period of 30 days of such shares becoming
due to be transferred to the IEPF Account. During the year
under review, there were no shares on which the dividend(s)
remained unpaid or unclaimed for 7 consecutive years.
Accordingly, no shares were required to be transferred by the
Company to the IEPF Account.

The number of shares (in respect of which dividend was not
claimed by the concerned shareholders for 7 consecutive years
or more) transferred and held by IEPF Authority is given in
the Corporate Governance Report forming part of the Annual
Report. The details of the persons whose shares have been
transferred to the IEPF Authority are available on the Company's
website at the link i.e. https://www.panaceabiotec.com/en/
section/information-repository/other-important-information.

Directors' Responsibility Statement

Based on the framework of internal financial controls and
compliance systems established and maintained by the
Company, work performed by the internal, statutory, cost,
secretarial auditors and external agencies, including audit
of internal controls over financial reporting by the Statutory
Auditors and the reviews performed by Management and the
relevant Board Committees, including the Audit Committee,
the Board is of the opinion that the Company's internal financial
controls were adequate and effective during the financial year
2025-26.

Accordingly, pursuant to Section 134(3)(c) read with Section
134(5) of the Act, the Board of Directors, to the best of their
knowledge, belief and according to the information and
explanations provided to them, confirmed that:

a) in the preparation of the annual financial statements for
the financial year ended March 31, 2026, the applicable
Accounting Standards have been followed along with
proper explanation relating to material departures;

b) they have selected such accounting policies and applied
them consistently and made judgments and estimates
that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the Company as at March
31, 2026, and of loss of the Company for the year ended
March 31,2026;

c) they have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance
with the provisions of the Act for safeguarding the assets of
the Company and for preventing and detecting fraud and
other irregularities;

d) the annual financial statements have been prepared on a
going concern basis;

e) they have laid down proper internal financial controls to be
followed by the Company and that the same are adequate
and were operating effectively; and

f) proper systems have been devised to ensure compliance
with the provisions of all applicable laws and that such
systems were adequate and operating effectively.

Details in respect of frauds reported by auditors

During the year under review, no fraud has been reported
by the auditors to the Audit Committee or the Board under
Section 143(12) of the Act and therefore, disclosure of details
under Section 134(3)(ca) is not applicable.

Particulars of loans, guarantees or investments

Pursuant to the provisions of Section 134(3)(g) of the Act, the
particulars of loans / guarantees and investments covered
under the provisions of Section 186 of the Act along with the
purpose for which such loans, guarantees or security were
proposed to be utilised by the recipient, have been disclosed
in the Note Nos. 3, 4 and 12 of the Standalone Financial
Statements forming part of the Annual Report and hence not
repeated here for the sake of brevity.

Risk Management

The Board of Directors has a Risk Management Committee to
oversee various organizational risks and to frame, implement
and monitor the risk management plan for the Company. Risk
Management Committee is compliant with Regulation 21 of
the SEBI LODR Regulations as regards composition, frequency
and quorum of the meetings. The Board has defined the roles,
responsibilities and functions of the Committee. The details of
the composition, the number of meetings held and attendance
thereat during the financial year under review and terms of
reference are furnished in the Corporate Governance Report,
forming part of the Annual Report.

The Company has formulated a Risk Management Policy and
monitors the risk management plan on a periodic basis. The
Audit Committee has additional oversight in the area of financial
risks and controls. The Company has defined a structured
approach to manage uncertainty and to make use of these in
decision making in business decisions and corporate functions.

Insurance

The Company has regularly invested in insuring itself against
unforeseen risks. The Company's stocks and insurable assets
like building, plant & machinery, computer equipment, office
equipment, furniture & fixtures, leasehold improvements and
upcoming projects have been adequately insured against
major risks. The Company has also taken appropriate product
liability insurance policies for conducting clinical trials and for
insuring its products (manufactured and sold) with an extension
of unnamed vendor liability and add on cover of public liability
inclusive of pollution liability to cover the risk on account
of claims, if any, filed against the Company. Pursuant to the

provisions of Regulation 25(10) of the SEBI LODR Regulations,
the Company has Directors' and Officers' Liability insurance to
cover the personal liability of directors and officers which may
arise while performing duties in their respective capacities on
behalf of the Company.

Internal Control System

Your Company has established an adequate system of internal
controls, policies and procedures to ensure orderly and efficient
conduct of business and also that assets are safeguarded
and transactions are appropriately authorized, recorded and
reported.

The detailed explanation is provided in the Management
Discussion and Analysis Report, forming part of the Annual
Report.

Internal Financial Controls

The Company has designed and implemented a process driven
framework for Internal Financial Controls ("IFC") within the
meaning of the explanation to Section 134(5)(e) of the Act.
Our IFC framework includes elements like orderly & efficient
conduct of business, safeguarding of assets adherence to
company policies, prevention and detection of fraud & errors,
accuracy & completeness of accounting records, and timely
preparation of reliable financial information.

The IFC framework is aligned with globally recognised
standards and supports the preparation of Financial Statements
that present a true and fair view in accordance with applicable
accounting principles. For the financial year ended on March
31, 2026, the Board is of the opinion that the Company has
sound IFC commensurate with the size, scale and complexity of
its business operations.

The IFC operates effectively, and no material weakness exists.
The effectiveness of IFC is ensured through management
reviews, controlled self-assessment and independent testing
by the internal audit team, and Audit Committee oversight.

Vigil Mechanism / Whistle Blower Policy

Your Company adheres to uncompromising integrity in
conduct of its business and strictly abides by a well-accepted
norm of ethical, lawful and moral conduct. It has zero
tolerance for any form of unethical conduct or behaviour.
With the above said view and pursuant to the provisions of
Section 177(9) of the Act read with Rule 7 of the Companies
(Meetings of Board and its Powers) Rules, 2014, Regulation
22 of the SEBI LODR Regulations and Regulation 9A of
Securities and Exchange Board of India (Prohibition of Insider
Trading) Regulations, 2015, your Company has adopted a Vigil
Mechanism / Whistle Blower Policy to provide its directors,
employees and other stakeholders an avenue to raise any
sensitive and genuine concerns regarding any unethical
behaviour or wrongful conduct and to enable them to report
instances of leak of unpublished price sensitive information
and to provide adequate safeguards for protection from any
victimization.

This Policy is available on the website of the Company and can
be accessed at: https://www.panaceabiotec.com/en/section/
information-repository/policy. This Policy, inter-alia, provides
direct access to the Chairman of the Audit Committee. Further,
as mandated by Regulation 18(3) read with Para A (18) of
Part C of Schedule II of the SEBI LODR Regulations, the Audit

Committee reviews the functioning of Vigil Mechanism /
Whistle Blower Policy.

Your Company hereby affirms that no director / employee has
been denied access to the Chairman of the Audit Committee
and that no complaint has been received by the Company
during the year under review.

Corporate Social Responsibility

The provisions of Section 135 of the Act and the Rules made
thereunder regarding Corporate Social Responsibility are
not attracted to the Company as the Company does not fall
under the threshold limit of net worth of ?5,000 million or
more, or turnover of ?10,000 million or more, or a net profit (as
defined under Section 198 of the Act) of ?50 million or more
during the immediately preceding financial year. However, the
Company has been, over the years, pursuing Corporate Social
Responsibility by putting continuous efforts in the areas of
health, education and patient awareness / assistance programs
towards the development of a happier and healthier society.

Prevention of Sexual Harassment at Workplace

The Company is committed to provide a safe and conducive
work environment to all its employees and associates. It is the
continuous endeavour of the Management of the Company to
create and provide an environment to all its employees that
is free from discrimination and harassment including sexual
harassment. The Company has in place a Policy on Prevention
of Sexual Harassment in line with the requirements of The
Sexual Harassment of Women at the Workplace (Prevention,
Prohibition and Redressal) Act, 2013 ("POSH Act"). All the
employees (permanent, contractual, temporary, trainees) are
covered under this policy.

During the financial year ended on March 31, 2026, the
Company conducted virtual training sessions for employees
to build awareness about the Policy and the provisions of the
POSH Act. Your Company has complied with the provisions
relating to constitution of Internal Complaints Committee
under the POSH Act for dealing with the complaint, if any,
relating to sexual harassment of women at workplace.

The details of sexual harassment complaint received and
disposed-off during the period under review are as follows:

Number of

Number of

Number of cases

complaints of

complaints

pending for more

sexual harassment

disposed off

than ninety days

received in the year

during the year

1

1

Nil

Maternity Benefits

The Company is committed to upholding the rights and
welfare of its women employees and has complied with the

provisions of the Maternity Benefit Act, 1961, and the rules
made thereunder, as amended from time to time. All eligible
women employees are provided maternity leave and other
benefits in accordance with the applicable provisions of the
Maternity Benefit Act, 1961. The Company has also ensured a
safe and supportive working environment, including provisions
for creche facilities where applicable, in line with statutory
requirements.

The Company continues to remain in full compliance with the
provisions of the Maternity Benefit Act, 1961, and confirms that
there have been no instances of non-compliance or adverse
findings in this regard during the financial year under review.
During the year under review, 14 (fourteen) female employees
have taken such benefits.

Proceeding under Insolvency and Bankruptcy Code, 2016

No application has been made under the Insolvency and
Bankruptcy Code, hence the requirement to disclose the
details of application made or any proceeding pending under
the Insolvency and Bankruptcy Code, 2016 during the year
along with their status as at the end of the financial year is not
applicable.

Cyber Security Incident

The Company has installed firewalls and other software to
protect against the cyber-crime. The back-ups are also being
kept on Cloud to prevent any kind of data loss. The Company
has also engaged an independent expert to verify the measures
already taken by the Company for safeguarding against any
cyber-attacks. No incident relating to cyber security, breaches
or loss of data or documents has been reported during the year
under review.

Acknowledgements

Your directors acknowledge with gratitude the co-operation
and assistance received from the WHO and other UN
Agencies, Central Government, State Governments and all
other Government agencies and the encouragement they
have extended to the Company. Your directors also thank
the shareholders, banks, customers, vendors and other
business associates for their confidence in the Company & its
management and look forward to their continuous support in
future. The Board wishes to place on record its appreciation for
the dedication and commitment of the employees at all levels
which has continued to be our major strength.

For and on behalf of the Board of
Panacea Biotec Limited

Sd/-

Place : New Delhi Dr. Rajesh Jain

Date : August 13, 2026 Chairman and Managing Director